Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.01 Insider Own7.70% Shs Outstand47.96M Perf Week10.65%
Market Cap1.02B Forward P/E- EPS next Y-3.37 Insider Trans4.23% Shs Float42.13M Perf Month53.55%
Income-218.20M PEG- EPS next Q-1.20 Inst Own77.40% Short Float53.70% Perf Quarter59.68%
Sales1.30M P/S781.75 EPS this Y-53.40% Inst Trans21.39% Short Ratio3.52 Perf Half Y-43.22%
Book/sh3.04 P/B6.97 EPS next Y25.80% ROA-96.60% Target Price18.54 Perf Year-16.93%
Cash/sh2.69 P/C7.87 EPS next 5Y-0.20% ROE-141.30% 52W Range8.00 - 41.97 Perf YTD-45.08%
Dividend- P/FCF- EPS past 5Y0.00% ROI-103.00% 52W High-48.80% Beta1.63
Dividend %- Quick Ratio2.90 Sales past 5Y-46.80% Gross Margin- 52W Low168.62% ATR2.39
Employees270 Current Ratio2.90 Sales Q/Q- Oper. Margin- RSI (14)58.96 Volatility12.25% 9.99%
OptionableYes Debt/Eq0.15 EPS Q/Q12.20% Profit Margin- Rel Volume1.23 Prev Close21.19
ShortableYes LT Debt/Eq0.10 EarningsMay 05 BMO Payout- Avg Volume6.44M Price21.49
Recom2.90 SMA2017.68% SMA5015.05% SMA200-16.26% Volume5,131,577 Change1.42%
May-03-16Downgrade Leerink Partners Mkt Perform → Underperform
Apr-29-16Downgrade Jefferies Hold → Underperform
Apr-26-16Reiterated RBC Capital Mkts Sector Perform $7.50 → $5
Apr-26-16Reiterated Needham Buy $53 → $20
Apr-26-16Downgrade Sun Trust Rbsn Humphrey Neutral → Reduce
Apr-26-16Downgrade Piper Jaffray Neutral → Underweight
Apr-22-16Reiterated RBC Capital Mkts Sector Perform $14 → $7.50
Mar-23-16Downgrade JMP Securities Mkt Perform → Mkt Underperform
Mar-01-16Reiterated Needham Buy $55 → $53
Jan-19-16Downgrade RBC Capital Mkts Outperform → Sector Perform $62 → $15
Jan-15-16Downgrade Piper Jaffray Overweight → Neutral
Oct-23-15Resumed BofA/Merrill Buy
Oct-23-15Initiated Jefferies Hold $28
Oct-02-15Reiterated Needham Buy $38 → $55
Aug-26-15Reiterated ROTH Capital Buy $50 → $45
Aug-26-15Reiterated ROTH Capital Buy $45 → $50
Aug-24-15Upgrade Piper Jaffray Neutral → Overweight $28 → $48
Aug-07-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
May-22-15Reiterated WBB Securities Strong Buy $25 → $35
May-21-15Downgrade BofA/Merrill Buy → Neutral
May-27-16 08:43AM  Is the FDAs decision to delay Sarepta drug decision good or bad? Nobody really knows at MarketWatch
08:33AM  Delayed FDA Decision Sends Sarepta Therapeutics Soaring
May-26-16 02:35PM  Sarepta: What the Bulls Say at
10:52AM  Sarepta: We've Seen This Before at
08:01AM  Trending Now: SRPT
12:11AM  [$$] Muscular Dystrophy Day at the FDA at The Wall Street Journal
May-25-16 09:16PM  [$$] Business Watch at The Wall Street Journal +26.63%
08:46PM  Should Investors Be Excited About Sarepta's Delay? at Motley Fool
07:38PM  [$$] Muscular Dystrophy Day at the FDA at The Wall Street Journal
06:48PM  Trade school: how to take advantage of weekly options at CNBC
05:41PM  Sarepta shares soar on FDA's eteplirsen review delay at CNBC
05:21PM  Why Computer Sciences, Sarepta Therapeutics, and Nimble Storage Jumped Today at Motley Fool
04:27PM  [$$] Sarepta Jumps on FDA Delay but Remains a Buy at
04:12PM  [$$] Sarepta: FDA's Decision on Dystrophy Drug Delayed at The Wall Street Journal
04:02PM  Sarepta Gets Second Wind, As FDA Delays Drug Decision Again
03:56PM  Sarepta (SRPT) Stock Spikes After FDA Delayed Approval Decision
03:45PM  [$$] How Options Investors Can Profit From Sarepta at
03:20PM  Dow jumps triple digits as oil hits 2016 high
02:25PM  Here's How to Trade 7 of the Market's Most-Active Stocks Right Now
02:05PM  Sarepta Therapeutics: Is This Why the FDA Delayed Its Decision? at
01:35PM  Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today?
01:35PM  Trending Tickers: SRPT, BABA, CSC, CHK, C
12:23PM  FDA delay raises slim hope for muscular dystrophy drug
12:15PM  Sarepta soars as FDA delays review of key drug
12:10PM  Sarepta Therapeutics: Not So Fast at
12:06PM  Sarepta Therapeutics Inc (SRPT) Soaring as FDA Postpones Eteplirsen Review, Raising Hopes of an Approval at Insider Monkey
11:57AM  Here's Why Sarepta Therapeutics' Stock Is Surging Higher Today at Motley Fool
09:38AM  A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review
09:25AM  Stocks to Watch: Sarepta, Hewlett-Packard Enterprises, Computer Sciences at The Wall Street Journal
09:24AM  Sarepta Therapeutics stock surges 22% in pre-market trade after drug decision is delayed at MarketWatch
09:03AM  Morning Movers: Sarepta Soars on FDA Delay; Tiffany Tumbles at
07:00AM  Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date Business Wire
07:00AM  Sarepta Surges After U.S. Regulators Delay Ruling on DMD Drug at Bloomberg
May-24-16 05:10PM  Xenoport Surges on Takeover Bid and Outperforms the Market +5.49%
01:41PM  Sarepta Therapeutics (SRPT) Stock Jumps on Possibility of New Drug Approval
May-23-16 05:48PM  Sarepta's wild ride -8.72%
10:49AM  2 Hotly Debated Drugs Due For FDA Decisions This Week
08:40AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : May 23, 2016
May-20-16 12:11PM  Sarepta awaits drug approval +8.81%
09:00AM  Sarepta AdCom Should Set The Record Straight at Forbes
May-19-16 04:20PM  Forget Sarepta Therapeutics, This DMD Stock Could Be A Better Buy at Motley Fool
May-16-16 09:00AM  Sarepta's AdCom Needs FDA's Permission To Speak Freely at Forbes
May-13-16 09:00AM  Sarepta AdCom's Potential Swing Votes at Forbes +5.72%
May-12-16 04:21PM  3 Risky Biotechs With FDA Decisions On Deck -- Are They Buys? at Motley Fool -7.30%
May-11-16 09:00AM  Sarepta AdCom Vote Should Be Treated Like A Mistrial at Forbes
May-10-16 05:08PM  CORRECTING and REPLACING Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
08:21AM  What's Sarepta Therapeutics Inc.'s Next Move? at Motley Fool
May-09-16 11:56PM  [$$] A Legal Test for the FDA at The Wall Street Journal
07:20PM  [$$] A Legal Test for the FDA at The Wall Street Journal
01:50PM  Wave to begin trials next year on 'more efficient' drug for Duchenne at
12:08PM  IHI Bucks the Downward Trend for the Week Ending May 6 Market Realist
May-08-16 09:45AM  4 Major FDA Decisions Expected by June at 24/7 Wall St.
May-05-16 04:50PM  Sarepta investor: High drug prices are good at CNBC
02:20PM  3 Things You Need to Know Now That Sarepta Therapeutics Has Reported First-Quarter Results at Motley Fool
12:34PM  Top fund manager on health care CNBC
12:31PM  Showdown over Sarepta's muscular dystrophy drug CNBC
07:24AM  Sarepta Therapeutics reports 1Q loss AP
07:07AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
07:00AM  Sarepta Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Developments Business Wire
06:48AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
May-04-16 04:13PM  [$$] Sarepta: A High-Risk, High-Return Trade at
May-03-16 02:26PM  [$$] Sarepta Could Triple on Expedited FDA Approval at
02:12PM  IBB Returns to Positive: How Did Its Holdings Perform? Market Realist
01:50PM  Put the trade on......NOW Yahoo Finance Contributors
12:20PM  What Caused Sarepta Therapeutics To Crash 29% in April at Motley Fool
12:00PM  Why it took so long for Sarepta to start a big trial of its Duchenne drug at American City Business Journals
10:31AM  'Confounding' Sarepta Could Tumble 75%, Leerink Says at
08:21AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : May 3, 2016 at Capital Cube
07:09AM  Sarepta Therapeutics downgraded by Leerink Partners
May-02-16 04:39PM  Sarepta shares soar after upgrade implies 322% upside at CNBC +26.29%
04:10PM  Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta at Motley Fool
03:52PM  Why Facebook, Opower, Genworth, Apollo Education, and Sarepta Are Spiking Today at Insider Monkey
02:05PM  Here's Why Sarepta Therapeutics (SRPT) Stock is Surging Today Zacks
11:10AM  Jim Cramer -- Following Nelson Peltz Can Make You a Ton of Money at TheStreet
09:55AM  Cramer's Stop Trading: Sarepta CNBC
May-01-16 10:55AM  5 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Apr-29-16 01:44PM  Will Sarepta Therapeutics (SRPT) Stock Be Hurt by Jefferies Downgrade? at TheStreet
12:41PM  Jefferies Cuts Sarepta To Sell, Sees Little Chance Of FDA Approval at
09:10AM  Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More at 24/7 Wall St.
09:00AM  Sarepta: FDA Policy Forced AdCom To Vote Against Patients' Interests at Forbes
12:37AM  [$$] Mental Dystrophy at the FDA at The Wall Street Journal
Apr-28-16 07:19PM  [$$] Mental Dystrophy at the FDA at The Wall Street Journal +19.48%
05:17PM  Sarepta Jumps On Hopes For Muscular Dystrophy Drug at
04:56PM  Is XBI Heading Back to Where It Started in April? Market Realist
02:35PM  Why Sarepta Therapeutics Inc. Is Up Big Today at Motley Fool
01:11PM  Why Are Investors Piling Into These Surging Stocks? at Insider Monkey
10:28AM  Jim Cramer -- Will FDA Approve Sarepta's Duchenne Drug After All? at TheStreet
10:17AM  Sarepta Can Win Speedy FDA Drug Approval at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead Zacks
09:27AM  Cramer's Mad Dash: Sarepta & PayPal CNBC
09:11AM  Sarepta Therapeutics shares surge 20% after article suggests drug approval possible at MarketWatch
Apr-27-16 04:07PM  Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News Zacks
10:17AM  Small Cap Watch: These 4 Stocks Are Making Big Moves Today Accesswire
09:35AM  These Five Stocks Could Be Ready To Double Heres Why! Accesswire
08:21AM  Despite Pleas, FDA Panel Shuns Drug at Motley Fool
07:20AM  More bad news for those that have this disease with no treatment at MarketWatch
Apr-26-16 07:15PM  Sarepta Shares Tumble Following FDA Committee's Decision Gurufocus -26.29%
04:04PM  The 52-Week Low Club for Tuesday at 24/7 Wall St.
03:03PM  [$$] Slim Sarepta Hopes Rest With Top FDA Official at
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; and a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEHRENS M KATHLEENDirectorMar 16Buy14.5410,000145,43321,855Mar 16 08:15 PM
BEHRENS M KATHLEENDirectorMar 14Buy16.5465,0001,075,276112,166Mar 16 08:15 PM
Barry RichardDirectorMar 14Buy15.6675,0001,174,1853,241,014Mar 16 08:09 PM